Anthill Ventures, an investment and scaling platform for early growth stage start-ups, on Tuesday announced its partnership with HealthCare Global Enterprises Ltd. (HCG), the largest provider of cancer care in India, to launch a market access programme for HealthTech start-ups.
Lumos is a 12-month programme designed for HealthTech start-ups with disruptive solutions and technologies within the core businesses of HCG which include oncology, fertility, precision medicine, genomics, research and diagnostics, as well as emerging areas across the healthcare ecosystem, said a statement from Anthill Ventures.
Anthill and HCG, along with their network of investors will invest up to $1 million in the HealthTech start-ups. The start-ups will also have access to new customers, get business mentoring and support in their growth journey, access to high end environment for faster product development, platform to showcase their products to the right market and opportunity to work on pilot projects through partnerships with corporates.
Bharani Setlur, Partner at Anthill Ventures and Programme Director, Lumos said through Lumos they were looking for the world's most innovative and disruptive healthcare technology start-ups that are ready to scale with speed.
B.S. Ajaikumar, Chairman and CEO of Healthcare Global Enterprises Ltd, said that Lumos brings about an opportunity to create disruption in multiple areas, including novel treatment ideas, enhanced patient experience as well as efficiency of healthcare operations.
--IANS
ms/anp/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
